August 2024
Astellas Employee Indicted by China’s Prosecutors on Espionage Charges
Astellas Pharma, China, Japan, espionage, indictment, diplomatic tensions
Biopharma Layoff Tracker 2024: Industry Continues to Downsize Amid Financial Pressures
Biopharma layoffs, job cuts, restructuring, financial pressures, industry trends
BridgeBio Unveils GondolaBio with $300M Investment, Transfers Key Programs to Joint Venture
BridgeBio, GondolaBio, Joint Venture, $300M Investment, Genetic Therapies, Biopharma Startup
Leqembi, Biogen and Eisai’s Alzheimer’s Drug, Gains UK Approval but Faces Cost-Effectiveness Hurdle
Leqembi, Alzheimer’s disease, UK approval, NICE, cost-effectiveness, Biogen, Eisai
FDA Rejects Regeneron’s Blood Cancer Bispecific, Delaying Competition with J&J and Pfizer
Regeneron, FDA rejection, blood cancer bispecific, linvoseltamab, multiple myeloma, J&J, Pfizer
Aadi Bioscience Cuts 80% of R&D Staff Amid Fyarro Expansion Setbacks
Aadi Bioscience, R&D workforce, Fyarro, expansion efforts, layoffs, pharmaceutical industry
BioMarin Appoints New R&D and Business Development Leaders
BioMarin, R&D, Business Development, Leadership, Greg Friberg, James Sabry, Hank Fuchs
PreciseDx Secures $20.7 Million in Series B Funding to Enhance AI-Driven Breast Cancer Risk Assessments
PreciseDx, AI-Powered Cancer Risk Assessments, Breast Cancer Diagnostics, Series B Funding, Precision Medicine
FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues
Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment
Biogen Faces Lawsuit Over Alleged Kickback Scheme to Block Generic Competition for Multiple Sclerosis Drug Tecfidera
Biogen, kickback scheme, Tecfidera, generics, multiple sclerosis, PBM, lawsuit